<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636008</url>
  </required_header>
  <id_info>
    <org_study_id>201919</org_study_id>
    <nct_id>NCT04636008</nct_id>
  </id_info>
  <brief_title>Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer</brief_title>
  <official_title>The Safety and Efficacy of Sintilimab Combined With Hypofractionated Radiotherapy in MSI-H/dMMR Rectal Cancer: a Prospective, Single-arm, Multicenter, Phase Ib Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yunnan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Cancer Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital Of Southwest Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>West China Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, single-arm study is conducted to investigate the safety and efficacy of&#xD;
      Sintilimab combined with hypofractionated radiotherapy in patients with microsatellite&#xD;
      instability-high (MSI-H)/ DNA mismatch repair-deficient (dMMR) non-metastatic rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients meet the inclusion criteria. After signing the informed consent, they are given&#xD;
      radiotherapy 5Gyx5 and sintilimab 200mg ivgtt D1, D15, D29. Radical surgery is performed 6-8&#xD;
      weeks after radiotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2020</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse reaction</measure>
    <time_frame>up to 10 weeks</time_frame>
    <description>Adverse reaction after receiving treatment of Sintilimab combined with hypofractionated radiotherapy and perioperative complications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>6-8 weeks after radiotherapy</time_frame>
    <description>Pathological response rate after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete resection rate</measure>
    <time_frame>6-8 weeks after radiotherapy</time_frame>
    <description>Complete resection rate after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>up to 10 weeks</time_frame>
    <description>Quality of life during treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Anti-PD-1 Antibody</condition>
  <condition>Radiotherapy</condition>
  <condition>Rectal Cancer</condition>
  <condition>MSI-H</condition>
  <condition>Mmr Deficiency</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sintilimab+Hypofractionated radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Sintilimab+Hypofractionated radiotherapy</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated Radiotherapy</intervention_name>
    <description>Hypofractionated Radiotherapy</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed rectal adenocarcinoma;&#xD;
&#xD;
          2. With DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H)&#xD;
             status, whether or not being Lynch syndrome;&#xD;
&#xD;
          3. Not received any anti-rectal cancer treatment previously; for patients with Lynch&#xD;
             syndrome, not received any anti-tumor therapy about rectal cancer diagnosed this time;&#xD;
&#xD;
          4. No distant metastasis except for lateral lymph nodes on thoracic and abdominal&#xD;
             enhanced computed tomography (CT) scans; the distance between tumor's lower edge and&#xD;
             anus within 15cm; clinical T stage ≥T2 on high-resolution pelvic magnetic resonance&#xD;
             imaging (MRI)；&#xD;
&#xD;
          5. Men and women ≥18 years of age;&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group performance status score 0 or 1;&#xD;
&#xD;
          7. Adequate hematologic, hepatic, renal, thyroid and cardiac function: hemoglobin ≥90&#xD;
             g/L, neutrophils ≥1500/mm3, platelets ≥75,000/mm3; aspartate aminotransferase and&#xD;
             alanine aminotransferase ≤3.0 × upper limit of normal (ULN), bilirubin ≤1.5 × ULN;&#xD;
             creatinine ≤1.5 × ULN, creatinine clearance ≥50 mL/min; activated partial&#xD;
             thromboplastin time, prothrombin time and international normalized ratio ≤1.5 × ULN;&#xD;
             serum albumin ≥28 g/L；thyroid stimulating hormone and free thyroxine within ±10% of&#xD;
             normal levels; no obvious abnormality in electrocardiogram;&#xD;
&#xD;
          8. Not received blood, blood products and hematopoietic growth factor (e.g. granulocyte&#xD;
             colony-stimulating factor) within 2 weeks before inclusion;&#xD;
&#xD;
          9. Informed consent form signed;&#xD;
&#xD;
         10. Life expectancy of ≥3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic disease history, severe hypersensitivity to drugs, antibody products or&#xD;
             Sintilimab;&#xD;
&#xD;
          2. Other malignancy history with disease free survival &lt;5 years, except for curative in&#xD;
             situ cervical cancer, curative skin basal cell carcinoma and curative gastrointestinal&#xD;
             cancer by endoscopic mucoresection;&#xD;
&#xD;
          3. Current or past history of autoimmune diseases, including but not limited to:&#xD;
             interstitial lung disease, uveitis, enteritis，active hepatitis (HBV DNA≥103 copies/mL&#xD;
             after regular antiviral therapy)，nephritis, hyperthyroidism and hypothyroidism;&#xD;
&#xD;
          4. Immunosuppressant or corticosteroid (systemic or local) use to suppress immune&#xD;
             function within 2 weeks before inclusion;&#xD;
&#xD;
          5. Severe infection needing intravenous antibiotics, antifungal agents or antiviral&#xD;
             drugs, et al;&#xD;
&#xD;
          6. Congenital or acquired immunodeficiency such as HIV infection; active Hepatitis B (HBV&#xD;
             DNA≥103 copies/mL after regular antiviral therapy);&#xD;
&#xD;
          7. Having one of the following complications: massive gastrointestinal hemorrhage,&#xD;
             gastrointestinal perforation or obstruction; symptomatic heart diseases including&#xD;
             unstable angina, myocardial infarction and heart failure; uncontrollable diabetes&#xD;
             mellitus or hypertension; uncontrollable diarrhea (interfering with daily activities&#xD;
             although receiving adequate treatment);&#xD;
&#xD;
          8. Bleeding tendency or receiving thrombolytic or anticoagulant therapy;&#xD;
&#xD;
          9. Pregnant or breastfeeding female; male and female unwilling to take any contraceptive&#xD;
             measures;&#xD;
&#xD;
         10. Psychiatric disorders that would interfere with cooperation with the requirements of&#xD;
             the study;&#xD;
&#xD;
         11. Other conditions that investigators consider not suitable for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meng Qiu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaofen Li, M.D.</last_name>
    <phone>+86-28-85422589</phone>
    <email>lxf0827@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofen Li, M.D.</last_name>
      <phone>+86-28-85422589</phone>
      <email>lxf0827@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>December 2, 2020</last_update_submitted>
  <last_update_submitted_qc>December 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>West China Hospital</investigator_affiliation>
    <investigator_full_name>Meng Qiu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

